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Background/Aims
Functional gastrointestinal disorders are those in which no abnormal metabolic or physical processes, which can account for 
the symptoms, can be identified. The irritable bowel syndrome (IBS) is a significant functional disorder, which affects 10-20 
percent of the population worldwide. Predominant symptoms of IBS are abnormal defecation associated with abdominal pain, 
both of which may be exacerbated by psychogenic stress. Our study was designed to test a hypothesis that symptoms in a 
subset of patients with a diagnosis of IBS are associated with an autoimmune degenerative neuropathy in the enteric nervous 
system.
Methods
Serum was collected from Rome II-IBS patients and controls at the University of North Carolina Functional Gastrointestinal 
Diseases Center. Assay procedures were immunohistochemical localization of antibody binding to enteric neurons and human 
protein microarray assay for antigens recognized by antibodies in the sera.
Results
Eighty-seven percent of IBS sera and 59% of control sera contained anti-enteric neuronal antibodies. Antibody immunostaining 
was seen in the nucleus and cytoplasm of neurons in the enteric nervous system. Protein microarray analysis detected antibody 
reactivity for autoantigens in serum with anti-enteric neuronal antibodies and no reactivity for the same autoantigens in sam-
ples not containing anti-enteric neuronal antibodies in our immunostaining assay. Antibodies in sera from IBS patients recog-
nized only 3 antigens out of an 8,000 immunoprotein array. The 3 antigens were: (1) a nondescript ribonucleoprotein 
(RNP-complex); (2) small nuclear ribonuclear polypeptide A; and (3) Ro-5,200 kDa. 
Conclusions
Results of the present study suggest that symptoms in a subset of IBS patients might be a reflection of enteric neuronal dam-
age or loss, caused by circulating anti-enteric autoimmune antibodies.
(J Neurogastroenterol Motil 2012;18:78-85)
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Figure 1. Method used to identify presence of anti-enteric neuronal antibodies in sera. (A) Structure of the anti-enteric neuronal antibodies. Serum
was applied to isolated longitudinal muscle with attached myenteric plexus (ie, longitudinal muscle-myenteric plexus preparation) or to isolated 
submucosal plexus free of the mucosa and muscularis externa (ie, submucosal plexus preparation). (B) Anti-enteric neuronal antibodies (human IgG),
if present in the serum, bind to antigenic molecules expressed by anti-enteric neuronal antibodies in neurons. Incubation with a fluorescently-tagged 
anti-human IgG antibody labels the neurons recognized by antibodies in the serum.
Introduction
The irritable bowel syndrome (IBS) is a functional gastro-
intestinal disorder (FGID). IBS diminishes quality of life for 
8%-20% of populations worldwide.
1-5 Predominant symptoms of 
IBS are abnormal defecation associated with abdominal pain, 
both of which may be exacerbated by psychogenic stress.
1,6
A disordered enteric nervous system (ENS) might underlie 
some forms of IBS pathophysiology.
7,8 Activity of the muscu-
lature, glands and vascular system to generate functionally effec-
tive patterns of behavior, which are adaptive for differing diges-
tive states, is controlled by the ENS. The gut does not work with-
out the ENS. This is apparent in its absence in terminal regions 
of the large intestine in Hirschsprung’s disease.
9 Autoimmune 
ablation of the ENS in the lower esophageal sphincter underlies 
the pathophysiology of achalasia.
10,11 Neuropathic degeneration 
of ENS neurons in IBS, gastrointestinal (GI) pseudoobstruction, 
Chagas disease, paraneoplastic syndrome and enteric ganglioni-
tis, underlies the morbidity.
12-20 Progressive degenerative loss of 
neurons from the ENS neural networks is reminiscent of dropout 
of dopaminergic neurons in Parkinson disease where gradual de-
pletion advances from minor symptoms to severe stages of so-
matic motor dysfunction. Progressive loss and degradation of 
ENS control of the gut musculature, glands and vasculature is 
expected to be likewise manifest as steady worsening of gut-re-
lated symptoms. 
Retrospective review suggests that IBS-like symptoms in a 
subgroup of patients might be an expression of early stages of a 
progressive degenerative ENS neuropathy that culminates as in-
testinal pseudoobstruction when neuronal loss reaches levels that 
compromise ENS programing of propulsive motility.
12,18,20 This 
is reminiscent of chronic GI pseudoobstruction in paraneoplastic 
syndrome where commonality of antigens between certain cancer 
cells (eg, small-cell lung carcinoma) and ENS neurons leads to 
autoimmune attack that destroys the neurons.
21 Patients with 
symptoms of pseudoobstruction in combination with small-cell 
lung carcinoma express IgG autoantibodies that bind to ENS 
neurons in the stomach and small intestine.
21,22 This damages, 
destroys and removes the neurons from the integrative neural 
networks through induction of apoptosis.
14
We aimed to evaluate the prevalence of anti-enteric neuronal 
antibodies in patients diagnosed with idiopathic IBS according to 
Rome II symptom-based criteria.
1,2 Our approach was based on 
one used productively by others for evaluation of anti-enteric 
neuronal antibodies in patients with the paraneoplastic synd-
rome.
21-23 Some of the results have appeared in abstract form.
24
Materials and Methods
Blood was drawn from 78 IBS patients and 22 controls in the 
Center for Functional GI and Motility Disorders at the 
University of North Carolina, Chapel Hill (UNC). Each patient 
reported symptoms of abdominal pain a minimum of 25% of the 
time in the last 3 months and met Rome II criteria for IBS as con-
firmed by UNC clinical gastroenterologists.
6 The controls, Jackie D Wood, et al
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which were recruited from the UNC gastroenterology unit and 
by public advertising, reported no significant recurring GI 
symptoms. The study was approved by the UNC institutional re-
view board and all subjects provided written informed consent.
Sera were separated, coded at UNC and transported frozen 
to The Ohio State University. Each sample was tested, in blinded 
manner, for presence of anti-enteric neuronal antibodies. The 
protocol consisted of incubation of whole-mount preparations of 
guinea pig ENS with patient or control sera followed by fluo-
rescent immunohistochemistry to visualize antibodies that recog-
nized ENS neurons (Fig. 1).
Whole-mount ENS preparations were obtained from male 
albino Hartley guinea pigs. The guinea pigs were killed by stun-
ning and exsanguination as approved by The Ohio State 
University ILAUC (Protocol 2010A0023; approved 2/11/2010; 
expiration 2/11/2013). The small intestine was removed, imme-
diately flushed with ice-cold Krebs solution and divided into seg-
ments that were fixed overnight in Zamboni’s fixative. Microdis-
section was used to prepare whole-mount preparations of the 
myenteric and submucosal plexuses for immunohistochemistry 
(Fig. 1A).
Whole-mount preparations were used for indirect immuno-
fluorescence screening for the presence of anti-enteric neuronal 
antibodies in the samples. The preparations were placed in phos-
phate buffered saline (PBS) containing 10% normal donkey se-
rum and 0.3% Triton X-100 for 30 minutes at room temperature 
followed by incubation in a serum sample overnight at room 
temperature. This was followed by washing the tissue in PBS and 
incubation in indocarbocyanin (Cy3)-labeled donkey anti-human 
IgG (1:500) at room temperature for 1 hour. The tissues were 
then washed in PBS and cover slipped with Vectashield
Ⓡ mount-
ing medium (Vector lab, Burlingame, CA, USA). Fluorescent 
labeling was viewed with a Nikon Eclipse 90i fluorescence micro-
scope (Nikon, Tokyo, Japan) and analyzed with filter combina-
tions that enabled separate visualization of multiple fluorophores. 
Photomicrographs were acquired with a CoolSnap HQ2 mono-
chrome digital camera (Roper Scientific, Tucson, AZ, USA), 
stored on disk and analyzed with MetaMorph
Ⓡ software 
(MetaMorph, Carl Zeiss Meditec, Göttingen, Germany). Speci-
ficity of labeling of ENS neurons by antibodies in the serum sam-
ples was verified by pre-absorbing antibodies in the sample with a 
liver substrate (100 mg/mL; Sigma-Aldrich, St. Louis, MO, 
USA) and finding no differences in immunostaining for serum 
exposed or not exposed to liver substrate.
22 Whole sections of liv-
er or kidney were exposed to serum samples that produced in-
tense neuronal staining and examined for fluorescent staining as 
an added control for specificity.
Serum samples were screened initially at a dilution of 1:50. 
When immunoreactivity was found, stepwise doubling of dilu-
tions was done until no staining above background was evident. 
The final dilution that yielded staining above background was re-
corded as the antibody titer. Samples were scored blindly by 3 ex-
perienced ENS histologists with a semiquantitative rating scale 
where: “0” = no neuronal fluorescent staining above back-
ground; “1” = moderate intensity of fluorescent staining; and 
“2” = intense fluorescent staining. Background staining was de-
fined as that produced when the secondary anti-human IgG anti-
body alone was applied.
Two-way contingency tables were generated with frequency, 
percentage, row percentage and column percentage. Fisher’s ex-
act test was used to test associations between 2 category variables. 
A P-value ＜ 0.05 represented statistical significance in hypoth-
esis testing.
The serum samples were analyzed with Invitrogen ProtoArray
Ⓡ 
human protein microarray immune response biomarker profiling 
kit (Cat. PAH0525102; Invitrogen, Carlsbad, CA, USA). 
Serum samples, which were determined to contain anti-enteric 
neuronal antibodies by immunostaining assay, were coded and 
compared blindly with a coded set that did not contain antibody 
immunoreactivity in the assay. We used Invitrogen’s ProtoArray
Ⓡ 
human protein microarray v4.1 immune response biomarker 
profiling kit (Invitrogen), which screens for 8,000 unique pro-
teins associated with the human immunoglobulin lambda locus. 
This locus is a region on chromosome 22 that contains genes for 
lambda antibody light chains.
ProtoArray data were analyzed with ProtoArray
Ⓡ Prospector 
v5.0 (Invitrogen). This is a freeware software program from 
Invitrogen
TM designed for identification of antibodies on the 
ProtoArray
Ⓡ microarray that are bound by extrinsic antibodies 
applied as a mixture of antibodies in a serum sample. ProtoArray
Ⓡ 
Prospector analyzes results where any bound antibody in the 
sample is detected by probing with a second fluorescently-la-
beled, IgG class-specific antibody. Binding of the second anti-
body on the microarray is then quantified by measuring the fluo-
rescence intensity of each spot on the microarray profile. Values 
(Z-factors) for the fluorescent signals are calculated by taking in-
to account corrections for background and negative controls on 
the microarray. The program identifies signals that have Z-fac-
tors greater than a user-defined cut-off; the cut-off was set at 0.4. 
Z-factors ＞ 0.4 were scored as positive “hits”. The program nor-Anti-Enteric Autoimmune Neuropathy
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Figure 2. Anti-enteric neuronal antibodies in serum from irritable bowel syndrome patient GCRC 2115. (A) Ganglion in the myenteric plexus stained
with fluorescently-labeled anti-human IgG following incubation with patient’s serum. Antibodies in the serum reacted with virtually all ganglion cells. 
Reaction is restricted to ganglion cell nuclei for this case. (B) The same ganglion stained with anti-human neuronal protein HuC/HuD, which identifies
all neuronal cell bodies in the ganglion. Anti-HuC/HuD immunoreactivity was expressed in the nucleus and cytoplasm and therefore outlined the entire
cell body. (C) Digital merger of patient’s antibody staining and anti-Hu. IBS, irritable bowel syndrome.
Table 1. Results for Irritable Bowel Syndrome Patients and Controls With or Without Anti-Enteric Neuronal Antibodies
Patients (n = 76)
Controls (n = 22)
IBS-C IBS-D IBS-A/M
Sex (n [%])
Female 6 (7.9) 15 (19.7) 34 (44.7) 22 (100)
Male 1 (1.3) 6 (7.9) 14 (18.4) -
Age (mean ± SD, yr)
Female 36.5 ± 12.0   30.9 ± 10.0 32.4 ± 12.6 39.6 ± 14.8
Male 32.0 ± 00.0 38.5 ± 6.2 31.6 ± 10.0 -
Stain (n)
Female
  0 2   2   4 9
  1 4 10 23 9
  2 0   3   7 4
Male
  0 0   1   3 -
  1 0   4   8 -
  2 1   1   3 -
Immunostain intensity was scored as 0 = no staining, 1 = moderate staining and 2 = intense staining for myenteric neurons. Mean stain intensity derived from scores
entered by 3 observers.
IBS-C, constipation predominant IBS; IBS-D, diarrhea predominant IBS; IBS-A/M, alternating/mixed IBS.
malizes values for fluorescence intensity and calculates Z-scores 
by subtracting the mean value of the entire population dis-
tribution and dividing by the standard deviation. Z-scores above 
a threshold of 3 were considered positive “hits”.
Results
Figure 2 illustrates results obtained with our immunofluore-
scent assay for presence of autoimmune anti-enteric neuronal an-
tibodies in IBS sera. Presence of anti-enteric neuronal antibodies 
was revealed as fluorescent staining of neuronal cell bodies fol-
lowing incubation with patients’ serum. The fluorescence was 
emitted from anti-human IgG antibodies, which were bound to 
anti-enteric neuronal antibodies in the serum, which in turn, were 
bound to antigens expressed by the neurons (Fig. 1). When an-
ti-enteric neuronal antibodies were present, double labeling with 
an antibody against the pan-neuronal marker HuC/D showed 
neurons to be the only cell type recognized by the antibodies (Fig. 
2A and 2B).
25 Sera from 78 IBS patients and 22 controls were 
examined. The patients were categorized as diarrhea predom-Jackie D Wood, et al
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Table 2. Results Obtained With Invitrogen, Inc. Immune Response Biomarker Profiling Assay
Protein name
IBS-A signal 
(density)
IBS-B signal 
(density)
IBS-A 
Z-score
IBS-B 
Z-score
IBS-A 
Z-factor
IBS-B 
Z-factor
IBS-A 
(hit)
IBS-B 
(hit)
Ribonucleoprotein complex 56,544.5 184 51.727 0.072 0.895 -6.286 1 1
Small nuclear ribonuclear polypeptide A 7,530 49 6.783 0.404 0.807 -7.820 1 0
Anti-Ro 5,200 MW 254,043.5 338.5 22.843 0.239 0.775 -6.494 1 0
IBS, irritable bowel syndrome; IBS-A, serum samples with anti-enteric nueronal antibodies; IBS-B, serum samples without anti-enteric neuronal antibodies.
Three blinded samples known to contain anti-enteric neuronal antibodies in immunostain assays (IBS-A) and 3 samples without antibodies in immunostain assays 
(IBS-B) were pooled. Out of 8,000 possibilities, 3 antigens were identified as reacting with antibodies in the IBS-A sera. No “hits” were obtained with IBS-B sera. The
3 identified antigens (“hits”) in IBS-A sera consisted of a nondescript ribonucleoprotein complex, Anti-Ro 52,000 MW and small nuclear ribonucleoprotein polypeptide A.
Figure 3. Immunostaining pattern for 
sera collected from 76 irritable bowel 
syndrome patients, 66 of whom had 
anti-enteric neuronal antibodies in their 
blood, and 22 controls, 13 of whom had 
anti-enteric neuronal antibodies in their 
blood. (A) Examples of immunostaining 
in the nucleus alone, the cytoplasm alone 
and in both nucleus and cytoplasm. (B) 
Immunostaining in the neuronal nuclei 
predominated relative to staining of the 
cytoplasm alone or staining of nuclei and 
cytoplasm. IBS, irritable bowel synd-
rome.
inant, constipation predominant or alternating/mixed according 
to Rome II criteria for IBS diagnosis.
1,6 Results for 76 patients 
(sera from 2 patients were compromised in handling) and the 
controls appear in Table 1.
Sera from 66 (86.8%) of the 76 tested IBS patients had anti-
bodies that bound and labeled ENS neurons (Table 1). Sera from 
the remaining 12 IBS patients did not have demonstrable an-
ti-enteric neuronal antibodies. Sera from 13 (59.1%) of 22 con-
trols contained the antibodies (Table 1). Antibody staining in-
tensities of “1” and “2” were treated as antibody presence and 
“0”-staining was treated as absence of antibodies in construction 
of a two-way contingency table. Fisher’s exact test was used to test 
for independence of association between the patient and control 
groups. The proportion of the patient group that had anti-enteric 
antibodies in the serum (ie, 66 of 76) was significantly different 
from the control group (ie, 13/22) with a P-value of 0.005. 
Antibody titers were variable in a wide range from 1:400 to 
1:409,600 for IBS patients (mean ± SD = 1:19,887 ± 67,932; 
n = 66) and 1:400 to 1:409,600 for controls (mean ± SD = 
1:118,500 ± 195,267; n = 13). The differences were significant 
(P ＜ 0.05; unpaired t test).
Antibody staining, when present in patient and control sera, 
occurred in the neuronal nuclei alone, in the cytoplasm alone or in 
both nucleus and cytoplasm (Fig. 3). Immunostaining in the 
neuronal nuclei predominated (78.5% of 79 samples) relative to 
staining of the cytoplasm alone (10.1% of the samples) or staining 
of both nuclei and cytoplasm (11.3%) for patients and controls 
(Fig. 3). There were no significant differences between males and 
females in terms of nuclear vs cytoplasmic vs nuclear and cyto-
plasmic staining.
The predominance of nuclear staining was consistent with 
the protein microarray data in Table 2. Analysis, with sensitivity 
for 8,000 human proteins associated with the immunoglobulin 
lambda locus, detected antibody reactivity for only three auto-
antigens in serum samples containing anti-enteric neuronal anti-
bodies, as determined by immunostain assay. No antibody re-Anti-Enteric Autoimmune Neuropathy
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activity for the same autoantigens was found in serum samples 
that did not contain the antibodies in our immunostain assay. 
Antibody titers for a nondescript macromolecular complex con-
taining both protein and RNA molecules (ie, ribonucleoprotein 
complex) and small ribonuclear polypeptide A were present in 
high titers in the same sera that contained anti-enteric neuronal 
antibodies in our neuronal assays. Moderate levels of anti-Ro 
52,000 MW antibody were present also in antibody-containing 
IBS sera and not in sera devoid of antibodies in immunostain as-
says (Table 2).
Discussion
Three outcomes are noteworthy in terms of the etiopatho-
genesis of IBS and FGIDs: (1) Anti-enteric neuronal antibodies, 
present in sera from IBS patients, suggest that an autoimmune 
degenerative neuropathy in the ENS might underlie their symp-
toms, (2) The high proportion of IBS patients with the antibodies 
in their blood (84.2%) is unexpectedly high and suggests that au-
toimmune damage and loss of neurons in the ENS might be an 
important factor underlying their symptoms and (3) The anti-en-
teric neuronal antibodies in IBS are directed only to three pre-
viously unrecognized kinds of antigens expressed by ENS neu-
rons and no other cell type in the intestine.
Anti-enteric neuronal antibodies in the IBS patients in our 
study are reminiscent of paraneoplastic neurological disease.
26 
Disordered gut motility associated with the paraneoplastic syn-
drome is explained as due to commonality of antigens between 
some cancers (eg, small-cell lung carcinoma) and ENS neurons. 
Antibody recognition of the antigens underlies the autoimmune 
attack, which results in decimation of neurons that form the ENS 
integrative circuitry.
27,28 The antibodies, after binding, induce 
apoptosis in guinea pig ENS neurons. Apoptosis in ENS neu-
rons involves mitochondrial events as indicated by specific activa-
tion of effector caspase-3 and the cytochrome C-dependent proa-
poptotic messenger apaf-1.
14 The neuronal autoantibody com-
monly associated with paraneoplastic dysmotility in the gut is the 
Type-1 anti-neuronal nuclear antibody.
29,30 This antibody binds 
to the nuclear protein Hu, which is part of a family of conserved 
RNA-binding proteins that includes HuC, HuD and HuR. 
These proteins are expressed in neurons of the ENS as well as 
other autonomic ganglia, sensory neurons and the central nervous 
system (Fig. 2B).
Irritable Bowel Syndrome Autoantibodies
Antibodies in IBS sera in the present study were restricted to 
recognition of only 3 antigens out of 8,000 in an immunoprotein 
array. The 3 antigens were: (1) a nondescript ribonucleoprotein 
(RNP-complex), (2) small nuclear ribonuclear polypeptide A 
and (3) Ro-5,200 kDa.
The IBS-related antigens are RNA-binding proteins like 
those of the Hu family, but otherwise different. This suggests 
that presence of autoantibodies, which recognize the 3 kinds of 
antigens, might prove to be a useful diagnostic marker for IBS 
and perhaps other FGIDs where disordered ENS function is 
suspect. RNP-complexes are involved in RNA processing and 
transport. TAR DNA-binding protein (TDP-43), the survival 
motor neuron protein and fragile-X mental retardation protein 
are three ubiquitous proteins of this nature mainly associated with 
defects in localized parts of the central nervous system.
31 Signifi-
cance of the RNP-complex in ENS neurons and susceptibility to 
disruption by autoantibodies is unexplored. The second antigen, 
small nuclear ribonuclear polypeptide A, also known as U-1A, is 
a 70 kDa peptide recognized by anti-ribonuclear protein auto-
antibodies associated with mixed connective tissue diseases (ie, 
arthralgias, Raynaud’s phenomenon, arthritis, myositis, pulmo-
nary fibrosis and sclerodactyly.
32,33 Autoantibodies to the third 
antigen, Ro-5,200, were first reported in the serum of patients 
with Sjögrens syndrome.
34 Aside from Sjögrens syndrome, an-
ti-Ro 5,200 kDa reactivity is found in systemic lupus eryth-
ematosus, scleroderma, dermatomyositis and systemic sclero-
sis.
35,36
Our findings suggest that presence of antibodies to the three 
ribonuclear proteins might not be unique to IBS and that IBS can 
be added to the spectrum of disorders associated with autoanti-
body binding to ribonucleoproteins. The proportion of control 
sera with anti-enteric neuronal antibodies in our study is notice-
ably large and might be a reflection of the scope of the disorders 
associated with the autoimmune-ribonucleoprotein interface in 
tertiary medical care populations. Overall, we cannot exclude the 
possibility that some of the Rome II IBS patients and/or controls, 
with circulating antibodies to one or the other of the three ribonu-
cleoprotein antigens in our study, did not have an autoimmune 
disease.
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